Considering that different FREM2 mutation types may have different roles in the occurrence of rectal cancer, we divided the 36 FREM2-mutant COAD patients into two subgroups: patients with inactivating mutations (n = 27, including non-sense mutations and silent mutations), and patients with other non-silent mutation (n = 55). Here, FREM2 is linked to colon adenocarcinoma.